Acumen Pharmaceuticals (ABOS) Other Non Operating Income (2021 - 2026)
Acumen Pharmaceuticals recorded quarterly Other Non Operating Income of -$43000.0 in Q1 2026, down 975.0% quarter-over-quarter from -$4000.0 in Q4 2025, and up 32.81% year-over-year from -$32376.5 in Q1 2025.
Acumen Pharmaceuticals' Other Non Operating Income history runs 6 years deep, the most recent figure standing at -$43000.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income rose 32.81% year-over-year to -$43000.0; the TTM figure through Mar 2026 stood at -$156000.0 (up 87.91% YoY), while the FY2025 annual figure was -$266000.0, down 76.16% from the prior year.
- Other Non Operating Income came in at -$43000.0 for Q1 2026 at Acumen Pharmaceuticals, down from -$4000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $33000.0 in Q3 2024 to a low of -$1.4 million in Q4 2023.
- A 5-year average of -$193466.7 and a median of -$42000.0 in 2023 frame the typical range for Other Non Operating Income.
- Across the five-year window, Other Non Operating Income plunged 136100.0% in 2023 and soared 178.57% in 2024, its largest moves.
- Acumen Pharmaceuticals' Other Non Operating Income stood at $1000.0 in 2022, then slumped by 136100.0% to -$1.4 million in 2023, then rose by 12.43% to -$1.2 million in 2024, then surged by 99.66% to -$4000.0 in 2025, then plunged by 975.0% to -$43000.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered -$43000.0, -$4000.0, and -$69000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Acumen Pharmaceuticals | 164.37 Mn | 35.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -43,000.00 |
| Dec 31, 2025 | -4,000.00 |
| Sep 30, 2025 | -69,000.00 |
| Jun 30, 2025 | -40,000.00 |
| Mar 31, 2025 | -64,000.00 |
| Dec 31, 2024 | -1.19 Mn |
| Sep 30, 2024 | 33,000.00 |
| Jun 30, 2024 | -68,000.00 |
| Mar 31, 2024 | -50,000.00 |
| Dec 31, 2023 | -1.36 Mn |
| Sep 30, 2023 | -42,000.00 |
| Mar 31, 2023 | -4,000.00 |
| Dec 31, 2022 | 1,000.00 |
| Sep 30, 2022 | -2,000.00 |
| Mar 31, 2022 | 1,000.00 |
| Dec 31, 2021 | 4,000.00 |
| Sep 30, 2021 | 19,000.00 |
| Jun 30, 2021 | 19,000.00 |
| Mar 31, 2021 | 9,000.00 |